Recombinant Human cIAP-2 (HIAP-1) Protein, CF

R&D Systems | Catalog # 817-P2

R&D Systems
Loading...

Key Product Details

  • R&D Systems E. coli-derived Recombinant Human cIAP-2 (HIAP-1) Protein (817-P2)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

E. coli

Accession Number

Applications

Inhibition Activity
Loading...

Product Specifications

Source

E. coli-derived human cIAP-2/HIAP-1 protein
ATVID 10-His tag SIEGRA Human cIAP-2
(Asn2-Ser604)
Accession # Q13489
N-terminus C-terminus

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

N-terminal Sequence Analysis

Ala

Predicted Molecular Mass

71 kDa

SDS-PAGE

73 kDa, reducing conditions

Activity

Measured by its ability to inhibit DEVD-AFC cleavage activity in cell extracts activated by addition of cytochrome c and dATP.
The IC50 for this effect is 25-1000 nM.
Optimal dilutions should be determined by each laboratory for each application.

Formulation, Preparation, and Storage

817-P2
Formulation Supplied as a 0.2 μm filtered solution in HEPES, NaCl, DTT and Glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: cIAP-2/HIAP-1

cIAP-2 (also known as MIHC and HIAP-1) is a member of the inhibitor of apoptosis (IAP) family of proteins that inhibit the proteolytic activity of mature caspases. cIAP-2 has 3 BIR (baculovirus inhibitor of apoptosis) domains, a RING finger domain, and a caspase recruitment domain (CARD). cIAP-2 inhibits caspases through the direct interaction of its BIR domain with the active caspase. Caspase activity may be restored through interactions with the Reaper like motif on mitochondrial proteins such as SMAC/Diablo or HtrA2/Omi. cIAP-2 is reported to be cleaved by HtrA2/Omi.

References

  1. Roy, N. et al. (1997) EMBO J. 23:6914.
  2. Deveraux, Q. et al. (1997) Nature 388:300.
  3. Deveraux, Q. and J. Reed (1999) Genes & Develop. 13:239.
  4. Srinivasula, S.M. et al. (2003) J. Biol. Chem. 278:31469.
  5. Yang, Q-H. et al. (2003) Genes Dev. 17:1487.

Alternate Names

BIRC3, cIAP2, HIAP-1, MIHC

Entrez Gene IDs

330 (Human)

Gene Symbol

BIRC3

UniProt

Additional cIAP-2/HIAP-1 Products

Product Documents for Recombinant Human cIAP-2 (HIAP-1) Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human cIAP-2 (HIAP-1) Protein, CF

For research use only

Citations for Recombinant Human cIAP-2 (HIAP-1) Protein, CF

Customer Reviews for Recombinant Human cIAP-2 (HIAP-1) Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human cIAP-2 (HIAP-1) Protein, CF and earn rewards!

Have you used Recombinant Human cIAP-2 (HIAP-1) Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for Recombinant Human cIAP-2 (HIAP-1) Protein, CF (817-P2):

Materials
  • Jurkat E6 wild type cell extracts (see supplementary methods for preparation)
  • Extraction Buffer: 50 mM HEPES, 10 mM KCl, 5 mM EGTA, 1 mM MgCl2, 0.2% CHAPS, 0.2 mM DTT, pH 7.5
  • Assay Buffer: 10 mM HEPES, 0.5 mM EGTA, 5 mM DTT, 10% Glycerol, pH 7.5
  • Recombinant Human cIAP‑2/HIAP‑1 (rhcIAP-2) (Catalog # 817-P2)
  • Cytochrome C, Bovine heart (Sigma, Catalog # C3131), 2 mg/mL stock in deionized water
  • dATP (Sigma, Catalog # D6500), 10 mM stock adjusted to pH 7.5 with NaOH
  • Cell Extracts from Jurkat E6 wild type cells (see above protocol)
  • Substrate: Ac-Asp-Glu-Val-Asp-AFC (DEVD-AFC) (MP Biomedicals, Catalog # AFC138), 10 mM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

Note: All reagents and assay components should be kept on ice until use.

  1. Thaw cell extracts and centrifuge in a microcentrifuge at 14,000 rpms for 5 minutes at 4 °C. Transfer supernatants to chilled tubes and use within 1 hour.
  2. Prepare a curve of rhcIAP-2 (MW: 71,000 Da) in Extraction Buffer. Make the following serial dilutions: 2500, 1500, 500, 250, 50, 25, and 5 nM. Note: High point may not be achievable depending on lot received.
  3. Prepare the activator mixture by combining equal volumes of 2 mg/mL Cytochrome C and 10 mM dATP for working concentrations of 1 mg/mL and 5 mM, respectively.
  4. Prepare reaction mixtures in tubes by combining 10 μL of each rhcIAP-2 curve dilution, 10 μL of cell extract supernatant, and 5 μL of the cytochrome C/dATP activator mixture. Also, prepare the following controls:
    1. Total Control: 10 μL of Extraction Buffer, 10 μL of cell extract supernatant, and 5 μL of the cytochrome C/dATP activator mixture.
    2. Inactive Control: 15 μL of Extraction Buffer and 10 μL of cell extract supernatant.  The total reaction volume is 25 μL.
  5. Incubate for 60 minutes at 30 °C.
  6. After incubation, add 100 μL of Assay Buffer to each vial for a five-fold dilution. Mix briefly.
  7. Dilute Substrate to 100 μM in Assay Buffer.
  8. In a plate load 50 μL of diluted incubated reaction mixtures, and start the reaction by adding 50 μL of 100 μM Substrate.
  9. Read at excitation and emission wavelengths of 400 nm and 505 nm, respectively, in kinetic mode for 5 minutes.
  10. Derive the 50% inhibiting concentration (IC50) of rhcIAP-2 by plotting normalized activity vs. reaction concentration of rhcIAP-2 (step 4) with Semi-Log Fitting [y = A + B * Log(x)].  Solve for x when y = 50.
  11. Normalized activity may be determined using the following equation:
  12.      % Normalized Activity = Sample (RFU/min) - Inactive Control** (RFU/min) x 100%
    Total Control (RFU/min)

Per Reaction:

  • rhcIAP-2 curve:  1000, 600, 200, 100, 20, 10, and 2 nM
  • Substrate: 50 μM

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes